🚀 VC round data is live in beta, check it out!
Rani Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Rani Therapeutics and similar public comparables like Hamlet BioPharma, Zomedica, Starpharma, Cardiff Oncology and more.
Rani Therapeutics Overview
About Rani Therapeutics
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Founded
2021
HQ
Employees
106
Website
Sectors
Financials (LTM)
EV
$145M
Rani Therapeutics Financials
Rani Therapeutics reported last 12-month revenue of $6M.
In the same LTM period, Rani Therapeutics generated $6M in gross profit and had net loss of ($27M).
Revenue (LTM)
Rani Therapeutics P&L
In the most recent fiscal year, Rani Therapeutics reported revenue of $1M and EBITDA of ($51M).
Rani Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6M | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | $6M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($51M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4915%) | XXX | XXX | XXX |
| EBIT Margin | (648%) | XXX | (4825%) | XXX | XXX | XXX |
| Net Profit | ($27M) | XXX | ($30M) | XXX | XXX | XXX |
| Net Margin | (486%) | XXX | (2920%) | XXX | XXX | XXX |
| Net Debt | — | — | $21M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Rani Therapeutics Stock Performance
Rani Therapeutics has current market cap of $132M, and enterprise value of $145M.
Market Cap Evolution
Rani Therapeutics' stock price is $1.35.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $145M | $132M | 0.0% | XXX | XXX | XXX | $-0.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRani Therapeutics Valuation Multiples
Rani Therapeutics trades at 26.2x EV/Revenue multiple, and (2.9x) EV/EBITDA.
EV / Revenue (LTM)
Rani Therapeutics Financial Valuation Multiples
As of March 21, 2026, Rani Therapeutics has market cap of $132M and EV of $145M.
Equity research analysts estimate Rani Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rani Therapeutics has a P/E ratio of (4.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $132M | XXX | $132M | XXX | XXX | XXX |
| EV (current) | $145M | XXX | $145M | XXX | XXX | XXX |
| EV/Revenue | 26.2x | XXX | 141.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.9x) | XXX | XXX | XXX |
| EV/EBIT | (4.0x) | XXX | (2.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 26.2x | XXX | — | XXX | XXX | XXX |
| P/E | (4.9x) | XXX | (4.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Rani Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Rani Therapeutics Margins & Growth Rates
Rani Therapeutics' revenue in the last 12 month grew by 42%.
Rani Therapeutics' revenue per employee in the last FY averaged $0.1M.
Rani Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | 405% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4915%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (19%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 360% | XXX | 2329% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 391% | XXX | 2596% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 4925% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Rani Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hamlet BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Cardiff Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Oramed Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rani Therapeutics M&A Activity
Rani Therapeutics acquired XXX companies to date.
Last acquisition by Rani Therapeutics was on XXXXXXXX, XXXXX. Rani Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Rani Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRani Therapeutics Investment Activity
Rani Therapeutics invested in XXX companies to date.
Rani Therapeutics made its latest investment on XXXXXXXX, XXXXX. Rani Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Rani Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Rani Therapeutics
| When was Rani Therapeutics founded? | Rani Therapeutics was founded in 2021. |
| Where is Rani Therapeutics headquartered? | Rani Therapeutics is headquartered in United States. |
| How many employees does Rani Therapeutics have? | As of today, Rani Therapeutics has over 106 employees. |
| Who is the CEO of Rani Therapeutics? | Rani Therapeutics' CEO is Talat Imran. |
| Is Rani Therapeutics publicly listed? | Yes, Rani Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Rani Therapeutics? | Rani Therapeutics trades under RANI ticker. |
| When did Rani Therapeutics go public? | Rani Therapeutics went public in 2021. |
| Who are competitors of Rani Therapeutics? | Rani Therapeutics main competitors are Hamlet BioPharma, Zomedica, Starpharma, Cardiff Oncology. |
| What is the current market cap of Rani Therapeutics? | Rani Therapeutics' current market cap is $132M. |
| What is the current revenue of Rani Therapeutics? | Rani Therapeutics' last 12 months revenue is $6M. |
| What is the current revenue growth of Rani Therapeutics? | Rani Therapeutics revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Rani Therapeutics? | Current revenue multiple of Rani Therapeutics is 26.2x. |
| Is Rani Therapeutics profitable? | No, Rani Therapeutics is not profitable. |
| What is the current net income of Rani Therapeutics? | Rani Therapeutics' last 12 months net income is ($27M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.